Navigation Links
Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
Date:7/25/2011

PRINCETON, N.J. , July 25, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended June 30, 2011.

Financial ResultsRevenues were $0.2 million during the quarter ended June 30, 2011 compared to $0.2 million for the quarter ended June 30, 2010 and include amortization of up-front and subsequent collaborative and license payments received from Roche.

Net cash used in operating activities during the three months ended June 30, 2011 was $22.3 million. Pharmasset held $188.2 million in cash and cash equivalents as of June 30, 2011.

Total operating expenses for the quarter ended June 30, 2011 were $22.6 million as compared to $15.7 million for the same period in 2010.

Pharmasset reported a net loss of $22.6 million, or $0.60 per share, for the quarter ended June 30, 2011, as compared to a net loss of $16.0 million, or $0.50 per share, for the quarter ended June 30, 2010.

Recent Operational Highlights:-- Bristol-Myers Squibb initiated a combination trial with BMS-790052 and PSI-7977

-- Completed enrollment of ELECTRON's original four arms with PSI-7977

-- Expanded the ELECTRON trial with the addition of three new treatment arms

-- We were granted a US patent (US patent 7,964,580) titled 'Nucleoside Phosphoramidate Prodrugs' covering PSI-7977

-- Pharmasset and Tibotec announced a clinical collaboration to combine PSI-7977 and Tibotec's TMC435, a protease inhibitor

-- Reported SVR24 data from PROTON trial with PSI-7977 in genotype 2 or 3 patients

-- Roche disclosed that it expects to file, in 2014, an application for marketing approval of mericitabine

"Pharmasset had a very successful f
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
2. Pharmasset to Present at Two Upcoming Investor Conferences
3. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
4. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
5. Pharmasset to Webcast an Investor Event From the EASL Meeting
6. Pharmasset to Present at Three Upcoming Investor Conferences
7. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
8. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
9. Pharmasset Announces Exercise of Underwriters Overallotment Option
10. Pharmasset Prices Public Offering of Common Stock
11. Pharmasset Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2
... ... ultrafiltration, NEW ... today that it will be exhibiting its Dual Stage,Ultrafilter products ... conference in Denver, Colorado, June,15th-19th, 2008. Building on the success ...
... BD (Becton,Dickinson and Company) (NYSE: BDX ), ... present at the Goldman Sachs Twenty-Ninth,Annual Global Healthcare Conference ... The live webcast of BD,s presentation can be accessed ... will be available for replay,through Wednesday, June 18, 2008., ...
... June 3 HLTH Corporation,(Nasdaq: HLTH ) ... definitive,agreement to sell its ViPS segment to General ... Dynamics Corporation,(NYSE: GD ) for $225 million ... conditions, including the expiration or termination of the ...
... can produce tiny magnetic nuggets after the introduction of ... gene MagA could become a valuable tool for tracking ... (MRI), says Xiaoping Hu, PhD, professor of biomedical engineering ... , "We have found a very simple way to ...
... N.Y., June 3 MedAmerica reports 2007 was ... results. In,addition, MedAmerica outperformed the long-term care insurance ... annual sales rate of 10%. (LIMRA 2007), ... Rochester, NY),MedAmerica Insurance Company (Home Office: Pittsburgh, PA), ...
... On June 7, 2008 the Philadelphia,Physicians for Student ... in the Philadelphia School District. Student,athletes in Pennsylvania ... eligible,to compete in interscholastic activities. The standard physicals ... enough to identify some potentially,life-threatening conditions., The ...
Cached Medicine News:Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 2Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 3Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 4Health News:HLTH Announces Agreement to Sell ViPS Unit to General Dynamics for $225 Million 2Health News:HLTH Announces Agreement to Sell ViPS Unit to General Dynamics for $225 Million 3Health News:Philly's Top Doc's Organize to Help Prevent Young Athlete Deaths in Philadelphia 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: